The Effect of Ruxolitinib on the Expression of VEGF and HIF-1α in Leukemia HEL Cells

• Published in: Sichuan da xue xue bao. Journal of Sichuan University. Yi xue ban Vol. 47; no. 5; p. 669
• Main Authors: Xu, Qian, Liu, Gui-Min, Wang, Feng-Yun, Zhang, Li-Jun, Liang, Wen-Tong, Cheng, Zhi-Yong
• Format: Journal Article
• Language: Chinese
• Published: China 01.09.2016
• Subjects: Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit - metabolism; Janus Kinase 2 - metabolism; Leukemia - metabolism; Pyrazoles - pharmacology; Signal Transduction; Vascular Endothelial Growth Factor A - metabolism; Angiogenesis; Ruxolitinib; HIF-1α; VEGF; Myeloproliferative neoplasms
• ISSN: 1672-173X

To investigate the effect of Ruxolitinib on the expression of vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 α (HIF-1α) in HEL cells. he HEL cells were treated with Ruxolitinib in different concentrations (1 nmol/L, 5 nmol/L, 10 nmol/L, 50 nmol/L, 100 nmol/L, 500 nmol/L). The growth inhibition of Ruxolitinib on HEL cells was detected by CCK-8 assay;the mRNA expression level of were measured by RT-PCR and the protein level of p-JAK2, VEGF, HIF-1α were observed by Western blot after treated with Ruxolitinib for 24,48,72 h. Chick chorioallantoic membrane (CAM) test was used to testify the effect of Ruxolitinib on angiogenesis. Ruxolitinib with different concentrations could inhibit HEL cells proliferation. RT-PCR showed that the mRNA level of decreased in a concentration-dependent manner and Western blot demonstrated that the expression levels of p-JAK2, VEGF and HIF-1α were lower in Ruxolitinib treatment groups than those in control group ( <0.05) after HEL cells were treated with diff